Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021
ABSTRACT: Objectives: To determine the in vitro activities of ceftolozane/tazobactam (C/T) and comparators against Pseudomonas aeruginosa isolates cultured from hospitalised patient samples in Taiwan from 2012 to 2021 with an additional focus on the temporal and geographical prevalence of carbapene...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Journal of Global Antimicrobial Resistance |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213716523001030 |
| _version_ | 1797689484630818816 |
|---|---|
| author | James A. Karlowsky Mark G. Wise Tai-Chin Hsieh Hung-Chi Lu Wei-Ting Chen Ming-Huei Cheng Fakhar Siddiqui Katherine Young Mary R. Motyl Daniel F. Sahm |
| author_facet | James A. Karlowsky Mark G. Wise Tai-Chin Hsieh Hung-Chi Lu Wei-Ting Chen Ming-Huei Cheng Fakhar Siddiqui Katherine Young Mary R. Motyl Daniel F. Sahm |
| author_sort | James A. Karlowsky |
| collection | DOAJ |
| description | ABSTRACT: Objectives: To determine the in vitro activities of ceftolozane/tazobactam (C/T) and comparators against Pseudomonas aeruginosa isolates cultured from hospitalised patient samples in Taiwan from 2012 to 2021 with an additional focus on the temporal and geographical prevalence of carbapenem-resistant P. aeruginosa (CRPA). Methods: P. aeruginosa isolates (n = 3013) were collected annually by clinical laboratories in northern (two medical centres), central (three medical centres), and southern Taiwan (four medical centres) as part of the SMART global surveillance program. MICs were determined by CLSI broth microdilution and interpreted using 2022 CLSI breakpoints. Molecular β-lactamase gene identification was performed on selected non-susceptible isolate subsets in 2015 and later. Results: Overall, 520 (17.3%) CRPA isolates were identified. The prevalence of CRPA increased from 11.5%–12.3% (2012–2015) to 19.4%–22.8% (2018–2021) (P ≤ 0.0001). Medical centres in northern Taiwan reported the highest percentages of CRPA. C/T, first tested in the SMART program in 2016, was highly active against all P. aeruginosa (97% susceptible), with annual susceptibility rates ranging from 94% (2017) to 99% (2020). Against CRPA, C/T inhibited >90% of isolates each year, with the exception of 2017 (79.4% susceptible). Most CRPA isolates (83%) were molecularly characterised, and only 2.1% (9/433) carried a carbapenemase (most commonly, VIM); all nine carbapenemase-positive isolates were from northern and central Taiwan. Conclusion: The prevalence of CRPA increased significantly in Taiwan from 2012 to 2021 and warrants continued monitoring. In 2021, 97% of all P. aeruginosa and 92% of CRPA in Taiwan were C/T susceptible. Routine in vitro susceptibility testing of clinical isolates of P. aeruginosa against C/T, and other newer β-lactam/β-lactamase inhibitor combinations, appears prudent. |
| first_indexed | 2024-03-12T01:46:13Z |
| format | Article |
| id | doaj.art-3e5e47fbc6ff4a82ae065a886c5d8f5b |
| institution | Directory Open Access Journal |
| issn | 2213-7165 |
| language | English |
| last_indexed | 2024-03-12T01:46:13Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Global Antimicrobial Resistance |
| spelling | doaj.art-3e5e47fbc6ff4a82ae065a886c5d8f5b2023-09-09T04:55:12ZengElsevierJournal of Global Antimicrobial Resistance2213-71652023-09-0134106112Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021James A. Karlowsky0Mark G. Wise1Tai-Chin Hsieh2Hung-Chi Lu3Wei-Ting Chen4Ming-Huei Cheng5Fakhar Siddiqui6Katherine Young7Mary R. Motyl8Daniel F. Sahm9IHMA, Schaumburg, Illinois; Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, CanadaIHMA, Schaumburg, Illinois; Corresponding author. Mailing address: IHMA, 2122 Palmer Drive, Schaumburg, Illinois 60173.MSD Taiwan, Taipei, TaiwanMSD Taiwan, Taipei, TaiwanMSD Taiwan, Taipei, TaiwanMSD Taiwan, Taipei, TaiwanMerck & Co., Inc., Rahway, New JerseyMerck & Co., Inc., Rahway, New JerseyMerck & Co., Inc., Rahway, New JerseyIHMA, Schaumburg, IllinoisABSTRACT: Objectives: To determine the in vitro activities of ceftolozane/tazobactam (C/T) and comparators against Pseudomonas aeruginosa isolates cultured from hospitalised patient samples in Taiwan from 2012 to 2021 with an additional focus on the temporal and geographical prevalence of carbapenem-resistant P. aeruginosa (CRPA). Methods: P. aeruginosa isolates (n = 3013) were collected annually by clinical laboratories in northern (two medical centres), central (three medical centres), and southern Taiwan (four medical centres) as part of the SMART global surveillance program. MICs were determined by CLSI broth microdilution and interpreted using 2022 CLSI breakpoints. Molecular β-lactamase gene identification was performed on selected non-susceptible isolate subsets in 2015 and later. Results: Overall, 520 (17.3%) CRPA isolates were identified. The prevalence of CRPA increased from 11.5%–12.3% (2012–2015) to 19.4%–22.8% (2018–2021) (P ≤ 0.0001). Medical centres in northern Taiwan reported the highest percentages of CRPA. C/T, first tested in the SMART program in 2016, was highly active against all P. aeruginosa (97% susceptible), with annual susceptibility rates ranging from 94% (2017) to 99% (2020). Against CRPA, C/T inhibited >90% of isolates each year, with the exception of 2017 (79.4% susceptible). Most CRPA isolates (83%) were molecularly characterised, and only 2.1% (9/433) carried a carbapenemase (most commonly, VIM); all nine carbapenemase-positive isolates were from northern and central Taiwan. Conclusion: The prevalence of CRPA increased significantly in Taiwan from 2012 to 2021 and warrants continued monitoring. In 2021, 97% of all P. aeruginosa and 92% of CRPA in Taiwan were C/T susceptible. Routine in vitro susceptibility testing of clinical isolates of P. aeruginosa against C/T, and other newer β-lactam/β-lactamase inhibitor combinations, appears prudent.http://www.sciencedirect.com/science/article/pii/S2213716523001030Carbapenem-resistantPseudomonas aeruginosaCeftolozane/tazobactamTaiwanSMARTSurveillance |
| spellingShingle | James A. Karlowsky Mark G. Wise Tai-Chin Hsieh Hung-Chi Lu Wei-Ting Chen Ming-Huei Cheng Fakhar Siddiqui Katherine Young Mary R. Motyl Daniel F. Sahm Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 Journal of Global Antimicrobial Resistance Carbapenem-resistant Pseudomonas aeruginosa Ceftolozane/tazobactam Taiwan SMART Surveillance |
| title | Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 |
| title_full | Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 |
| title_fullStr | Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 |
| title_full_unstemmed | Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 |
| title_short | Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan—SMART 2012–2021 |
| title_sort | temporal and geographical prevalence of carbapenem resistant pseudomonas aeruginosa and the in vitro activity of ceftolozane tazobactam and comparators in taiwan smart 2012 2021 |
| topic | Carbapenem-resistant Pseudomonas aeruginosa Ceftolozane/tazobactam Taiwan SMART Surveillance |
| url | http://www.sciencedirect.com/science/article/pii/S2213716523001030 |
| work_keys_str_mv | AT jamesakarlowsky temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT markgwise temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT taichinhsieh temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT hungchilu temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT weitingchen temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT minghueicheng temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT fakharsiddiqui temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT katherineyoung temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT maryrmotyl temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 AT danielfsahm temporalandgeographicalprevalenceofcarbapenemresistantpseudomonasaeruginosaandtheinvitroactivityofceftolozanetazobactamandcomparatorsintaiwansmart20122021 |